Glucose-Insulin System based on Minimal Model: a Realistic Approach
|
|
- Kristopher Webb
- 8 years ago
- Views:
Transcription
1 th UKSIM-AMSS International Conference on Modelling and Simulation Glucose-Insulin System based on Minimal Model: a Realistic Approach Adriana Aguilera González, Holger Voos Interdisciplinary Centre for Security, Reliability and Trust (SnT) - University of Luxembourg L-1359, Luxembourg-Kirchberg, Luxembourg adriana.aguilera/holger.voos@uni.lu Mohamed Darouach CRAN-CNRS UMR 7039 Université de Lorraine, IUT de Longwy 54400, Cosnes et Romain, France mohamed.darouach@univ-lorraine.fr Abstract This paper presents a new approach to represent the glucose and insulin levels on patients with diabetes type 1 based on the well-known minimal model. In this work a new mathematical model is proposed which attempts modeling properly the malfunction of the pancreas. The model takes into account both: the description of the glucose level in the subcutaneous layer and a meal disturbance term. Further, also has an additional term that represents the insulin in a more realistic approach. In silico simulations are used for first evaluations of the proposed model effectiveness, considering variations on quantity of meals and of insulin supplied. Keywords glucose-insulin system; diabetes type 1; minimal model augmented I. INTRODUCTION Type 1 diabetes is a chronic and autoimmune disease. According to the World Health Organization in 2012, diabetes was the direct cause of 1.5 million deaths worldwide, and additionally in 2014, 9% of adults 18 years and older had diabetes. Type 1 diabetes is characterized by deficient or null insulin natural production, which causes deviations of the glucose concentration level in the bloodstream from normal values. Significant and prolonged deviations from the normal level can lead to numerous and serious pathologies as: adult blindness, end-stage renal failure, retinopathy, neuropathy, and lower-limb amputations. Therefore, diabetes represents a major threat to public health with alarmingly rising trends of incidence and severity in recent years; which motivates communities of control engineering, bio-engineering and medicine to continue efforts to improve engineering quality of life of patients. The current standard treatment procedure of diabetes primarily involves insulin medication coupled with strict dietary control. The insulin hormone is administered through discrete insulin injections, or through continuous subcutaneous infusion via an insulin pump. Discrete insulin injections is an open-loop process that is not an ideal treatment of diabetes, because several unknown factors exists which directly influence the level of glucose (meals, sport, mood, etc.). Continuous insulin infusion through a programmable insulin pump, on the other hand, offers a potential for a closed-loop control to regulate glucose. These new means offer the possibility to regulate the infusion rate in an individual form for each person. However, interpersonal variations are a big problem to regulate the level of glucose and make it difficult to determine an insulin dose for each particular patient. Some of these difficulties are: the variability of overnight insulin requirements, episodes of hyperglycemia after nocturnal hypoglycemia, variability of subcutaneous absorption of insulin or a defective counter-regulation of glucose. Therefore, closed loop control techniques are developed in order to maintain a normal physiological glucose level [1]. Human bodies need to maintain a glucose concentration level in a narrow range (70 110mg/dl or mmol/l after overnight fast). If the glucose concentration level is significantly out of the normal range, the person is considered to have a plasma glucose problem: hyperglycemia or hypoglycemia. The modelling of the glucose-insulin system has become an interesting topic and several models have been proposed towards a better understanding of the metabolic system, investigating possible pathways to control the diabetes as well as providing better insulin administration practices. In order to predict blood glucose concentrations, a model must incorporate such information as: 1) the effect of the blood glucose concentration and changes in the blood glucose concentration on beta cell insulin release; 2) the effect of exogenous insulin delivery into the subcutaneous or intravenous compartments on blood insulin levels; 3) the effect of food intake on glucose appearance into the circulation; and 4) the effect of a change in glucose appearance into the bloodstream combined with specified insulin levels on blood glucose concentrations [2]. In general, mathematical models have been used to estimate the glucose disappearance and insulin sensitivity which are used to study relative dependencies of insulin infusions. Different types of models which have been used in the literature can be classified mathematically as: ordinary differential equations [3], [4], [5], delay differential equations [6], [7], partial differential equations [8], [9], stochastic differential /15 $ IEEE DOI /UKSim
2 equations [10], [11] and integro-differential equations [12], [13]. Also, different software packages can be used for different types of models for numerical analysis and simulations. The so-called minimal model, is the model currently mostly used in physiological research on the metabolism of glucose and the insulin regulation. This model was proposed in the early eighties by [4] for the interpretation of the glucose and insulin plasma concentrations following the intravenous glucose tolerance test (IVGTT). The minimal model is commonly used to analyze the results of glucose tolerance tests in humans and laboratory animals. For instance, a model predictive controller (MPC) using the minimal model was implemented by authors in [14], in order to return the blood glucose to normoglycemic ranges when subjected to a meal disturbance. In the same way, [15] propose a mathematical model which takes into account all plasma glucose concentration, generalized insulin and plasma insulin concentration. This model shows a long-term diabetes progression but not considers the meals disturbance. Similarly, in [16] a mathematical model for describing the glucose infusion rate was introduced based on the minimal model. A glucose-insulin system was generated to obtain the real optimized model parameters, from the experimental data using the modified minimal model. Equality important is the parameter estimation, for this, the authors in [17] present a novel approach for guaranteed the parameter estimation of the minimal model based on the Set Inversion via Interval Analysis (SIVIA) algorithm. In this work, the proposed model takes into account three main conditions that must be considered for successful treatment of the disease. These three conditions are: i). The description of the glucose level in the subcutaneous layer, which it is very important because the measurements of glucose level and the insulin injections via a insulin pump, are made subcutaneously. ii). A meal disturbance term it is considered into the model because is a variable that have an important influence on the system, causing deviations from the normal glucose level. iii). A term that allows to represent the insulin dose considering the type, which it is very important factor due that the insulin is classified by how fast they start to work and how long their effects last. Consequently, to consider these aspects our model becomes in an approach more realistic. The paper is organized as follows. The minimal model and its basic properties are described in Section II. In Section III some extensions are introduced that are necessary in order to adapt the model in a better way to reality. In the Section IV simulation results are presented and discussed. Section V provides the conclusions and comments. II. MINIMAL MODEL: PRELIMINARS The origin of the minimal model began with the idea to construct a mathematical model of the pancreatic islets, which was a particularly difficult problem, due to the fact that beta-cell have a complex behavior, with a response that is altered by previous history of stimulation and a non-linear dose response curve. Bergman et. al. in [4], via intravenous glucose tolerance test (IVGTT) modified, achieved revealing the complex dynamic relationship between plasma glucose and insulin and they concluded that the resulting data can be described by a stimulus-response (input-output) model of the extra pancreatic tissues that utilize glucose. Such model it is considered as being simple enough to account totally for the measured glucose (given the insulin input), however allows, using mathematical techniques, to estimate all the characteristic parameters of the model from a single data set (thus avoiding unverifiable assumptions) [18]. Figure 1. Minimal model of glucose disappearance [4] Figure 2. Minimal model of insulin kinetics [4] Glucose minimal model involves two physiological compartments: a glucose compartment, whereas plasma insulin is assumed to act through a remote compartment to influence net glucose uptake (see Figs. 1-2). The minimal model attempts to describe the dynamics of the system as simply as possible, dividing the model in two parts: the Eqs. (1-56
3 Figure 3. Blood glucose level using the minimal model for a normal patient. Figure 4. Blood insulin level using the minimal model for a normal patient. 2) which describe the glucose plasma concentration timecourse treating insulin plasma concentration as a known forcing function (it is represented by Fig. 1). These equations are: dg dt = p 1G X(G + G b ) (1) dx dt = p 2X + p 3 I (2) where G is the blood glucose concentration, X is the effect of active insulin, I is the plasma insulin concentration, G b and I b are the basal values of glucose and insulin concentration, p 1 is the glucose clearance rate independent of insulin, p 2 is the rate of clearance of active insulin (decrease of uptake) and p 3 increase in uptake ability caused by insulin. Eq. (3) consists of a single equation, which describes the time course of plasma insulin concentration treating glucose plasma concentration as a known forcing function (it is represented by Fig. 2). di dt = n[i Ib]+γ(G h)+ t (3) where n is the fractional disappearance rate of insulin, γ is the rate of pancreatic release after glucose bolus, h is the target glucose level and t represents the time interval from the glucose injection, (values and units of this variables can be seen in the Appendix, Table I). This function was firstly presented by [4] and adjusted by [12]. Only the positive part of the term (G(t) h) is taken, otherwise the value is zero. Therefore h is considered as a threshold level to decide when the pancreas should produce more insulin and when to stop, finally the difference between G(t)h determines how much it should be produced. The reason for the multiplication with t is because the pancreas response is proportional not only to the hyperglycemia attained but also to the time elapsed from the glucose stimulus. Figs. 3-4 shown the glucose and insulin levels of a normal patient. It is possible to see that the glucose level reaches its basal level at 60 minutes approximately, and so does insulin, too. This model is useful to represent a normal patient, since it describes the pancreas as the source of insulin. In a healthy person a small amount of insulin is always created or cleared. This helps to keep the insulin basal concentration I b. If the insulin level is above basal concentration the clearance increases, if the insulin level is below basal concentration the basal production increases. When the glucose level gets high the pancreas reacts by releasing more insulin at a certain rate. The minimal model is still classified as a very simple model of the dynamics of the interaction of blood glucose and insulin, it retains some compatibility with known physiological facts and has been validated in a number of clinical studies [19]. However, to use this model for a diabetic patient Type 1, it is necessary to introduce some changes into the minimal model. Some variables and functions will be added in order to have a more approximate representation of reality and daily conditions of the patient. III. MINIMAL MODEL ADAPTED TO TYPE 1DIABETIC PATIENT It is possible to increase the functionality of the glucose minimal model, thus it could be used to simulate more than an IVGTT, for which some additions could be done. The first of these additions corresponds to a function describing what a meal would do to the glucose level. This is done by adding a meal disturbance term called D(t) to Eq. (1). To represent a person in a diabetic state, the original minimal model is described by the following differential equations: dg dt = p 1G X(G G b )+D(t) (4) dx dt = p 2X + p 3 I (5) where the parameters p 1, p 2, p 3, and V G should be estimated via mathematical methods. D(t) represents the 57
4 meal disturbance that can be normalized to the subject s body weight m BW and the glucose distribution volume V G for do it explicit the appearance of exogenous glucose into the minimal model [20], [21], [22]. D(t) can be obtained as follow: D(t) = R abs (6) m BW V G where R abs is the rate of absorption (mg/min) and is simply scaled by the glucose distribution volume V G and for the body weight m BW, in order to determine the glucose infusion rate per volume. This model can be adapted to change basal blood glucose concentrations and to body mass, where the parameters are previously known, i.e., can be adapted to each patient [23]. This process of meal absorption needs a description, which was suggested by [19] as follows: R abs (t) =B e (drate t) (7) The author suggested that the meal absorption description should be a function which rapidly increases after the meal, and then decays to 0 in 2-3 hours. Like the glucose model, the insulin model is used to interpret the IVGTT. That simplifies any interpretation of the model, however complicates the description of the insulin kinetics for a type 1 diabetic person with no endogenous insulin production. Therefore, it is possible to modify this condition by exchanging the incoming part representing the pancreas by a function U(t) that describes exogenous or endogenous insulin infusion [14]. This modification is presented as follow: di dt = n(i I b)+ U I(t) (8) V I where endogenous insulin secretion (i.e. the term σ(g(t)h)t) in Eq. (3) was removed, and the terms of exogenous infusion of insulin U I (t) was added. V I is the distribution volume of insulin in blood that should be estimated. The exogenous infusion of insulin (U I (t)) can be modeled as the rate of insulin absorption after a subcutaneous insulin injection according to authors in [24], as follow: U I (t) = s it si T si 50 D I t[t si 50 + ] tsi 2 (9) where t is the time elapsed from the injection (t s means t raised to the power s i ), T 50 is the time at which 50% of the insulin dose D I has been absorbed and s i is a parameter which defines the insulin absorption pattern depending of types of insulin (regular, intermediate, slow, etc.). The linear dependency of T 50 on dose is defined as: T 50 = a i D I + b i (10) where a i and b i are preparation-specific parameters the values of which are given in [24] along with values for s i. In order to make the proposed model more realistic, another addition which could be done is a description of the glucose level in the subcutaneous layer. A patient with type 1 diabetes, usually test their blood sugar frequently (3 to 10 times per day), both to assess the effectiveness of their prior insulin dose and to help determine their next insulin dose. For this reason, it is more easy to do the blood glucose concentration monitoring through the subcutaneous layer measurements and not via intravenous, in order to avoid invasive techniques. For the purpose of simplifying any later comparison with measured data, the function G sc (t) is introduced, which describes the glucose concentration in the subcutaneous layer. A differential equation describing this behavior is introduced with the following function: dg sc dt = G(t) G sc 5R utl G sc (0) = G(0) 5R utl (11) This equation models a first-order delay (5 minutes) between the blood glucose concentration and the subcutaneous glucose concentration. The R utl, is the rate of utilization, which is the difference between the two concentrations in the steady state [25]. One of the major problems concerning creating a artificial pancreas, is the delay between these two concentrations. IV. RESULTS AND DISCUSSION In Fig. 5 the result of three meals of different sizes are given, using the meal disturbance function given by Eq. (7) and values of B =3,B =5and B =12. These figures show that the glucose level rises and then decays inside a 1.5 hours period. This fast clearance of glucose is most likely due to the value parameters estimated by [14]. So p 1 should have a lower value, which would slow down the decay. But this example was just to show that the model reacts to the meal disturbance Eqs. (6-7). Figure 5. Subcutaneous and blood glucose level at different meal disturbance values and zero insulin. In Fig. 6 a day s scenario (24 hours) is presented including three meals: breakfast at 7:00a.m., lunch at 12:30p.m. and dinner at 7:00p.m.. In this figure it can be seen the increase of glucose levels in each meal and return to basal glucose 58
5 level between two or three hours after. This figure shows that the meal disturbance is an external variable that causes important deviations from the normal glucose level, which will be considered a completely unknown and individual disturbance. Figure 8. Subcutaneous and blood glucose level in 24h, three meals and three insulin injections response. Figure 6. Subcutaneous and blood glucose level in 24h, three meals and zero insulin. Fig. 7 presents 3 injections of size D I = 250mU of regular insulin at the meal times. The larger the dose of regular insulin, the faster the onset of action, but the longer the time to peak effect and the longer the duration of the effect. This figure shows the rate of insulin absorption after three subcutaneous insulin injections for a type 1 diabetic patient, without endogenous insulin production. Figure 7. Subcutaneous insulin level. In Fig. 8 it is shown a comparison between a profile without insulin therapy (as shown in Fig. 6) and a profile with insulin injections. The insulin was supplied at the same time as the meals, and in the three cases the quantity was the same (D I = 250mU). It is possible to see that the glucose level is less in the case of insulin therapy and also, the time to come back a basal glucose level was less. This shows how the model describe an insulin injection effect on the glucose concentration. V. CONCLUSION An analysis about the minimal model of Bergman was presented. This model is considered the simplest and has been useful to identify important issues in systems biology as they relate to carbohydrate metabolism. In this paper, new modifications of the minimal model are provided in order to allow the exploration of new strategies to maintain blood sugar level in normal values. On the glucose-insulin system, usually multiple conditions are found as: insulin delays, physical activity, inaccessible/unmeasurable meal disturbances, etc., which hindering an accurate representation. The proposition presented in this work, is an alternative that seeks to obtain an more approximate model which allows to take into account these conditions. These auxiliary variables and functions result in a more realistic model, useful to develop control algorithms. Evaluating the performance, the proposed model has the possibility to represent the reaction to a meal disturbance and the reaction to a insulin injection or a change in basal insulin delivery. It could be used to give approximations how the glucose-insulin system would react in a certain situation and one of the advantages is that it is very easy to use. The most interesting function of the modified model is the possibility to attach a controller, which controls the glucose level by manipulating the insulin delivery U I. Which at same time allows represent the type of insulin used in the treatment. This feature makes it interesting, because one of the great issues in the diabetes treatment is the search of the best controller acting as an artificial pancreas. ACKNOWLEDGMENT The authors would like to thank the Fonds National de la Recherche (FNR) of Luxembourg for the financial support in the developing of the project I2R-DIR-AFR REFERENCES [1] D. Radomski, M. Lawrynczuk, M. Marusak and P. Tatjewski. Modeling of glucose concentration dynamics for predictive control of insulin 59
6 administration. Biocybernetics and Biomedical Engineering, 30(1), 41-53, [2] G. Steil, B. Clark, S. Kanderian and K. Rebrin. Modeling insulin action for development of a closed-loop artificial pancreas. Diabetes Technologies Therapy, 7, , [3] V. W. Bolie. Coefficients of normal blood glucose regulation. Journal of Applied Physiology, 16(5), , [4] R. Bergman, L. Phillips and C. Cobelli. Physiologic evaluation of factors controlling glucose tolerance in man. Journal of Clinical Investigation, 68(6), , [5] R. Parker, F. Doyle III and N. Peppas. A Model-Based Algorithm for Blood Glucose Control in Type I Diabetic Patients. IEEE Transactions on Biomedical Engineering, 46(2), , [6] K. Engelborghs, V. Lemaire, J. Bélair and D. Roose Numerical bifurcation analysis of delay differential equations arising from physiological modeling. Journal of Mathematical Biology, 42(4), , [7] D. Bennett and S. Gourley. Asymptotic properties of a delay differential equation model for the interaction of glucose with plasma and interstitial insulin. Applied Mathematical and Computation, 151(1), , [8] P. Wach, Z. Trajanoski, P. Kotanko and F. Skrabal Numerical approximation of mathematical model for absorption of subcutaneously injected insulin. Medical and Biological Engineering and Computing, 33(1), 18-23, [9] J.P. Keener Diffusion induced oscillatory insulin secretion. Bulletin of Mathematical Biology, 63(4), , [10] G. Bleckert, U. Oppel and E. Salzsieder Mixed graphical models for simultaneous model identification and control applied to the glucoseinsulin metabolism. Computer Methods and Programs in Biomedicine, 56(2), , [11] G. De Vries and A. Sherman Channel sharing in pancreatic - cells revisited: Enhancement of emergent bursting by noise.journal of Theoretical Biology, 207(4), , [12] A. De Gaetano and O. Arino. Mathematical modelling of the intravenous glucose tolerance test. Journal of Mathematical Biology, 40(2), , [13] J. Li, Y. Kuang and C. Mason. Modeling the glucose-insulin regulatory system and ultradian insulin secretory oscillations with two explicit time delays. Journal of Theoretical Biology, 242(3), , [14] S. Lynch and W. Bequette. Model Predictive Control of Blood Glucose in Type I Diabetics Using Subcutaneous Glucose Measurements Proceedings of the American Control Conference, Anchorage, USA, , [15] Sandhya and D. Kumar. Mathematical model for glucose-insulin regulatory system of diabetes mellitus. Advances in Applied Mathematical Biosciences, 2(1), 39-46, [16] K. Ab Kahar, M. Mamat, Z. Salleh and Z. Zakaria. Minimal modeling of glucose-insulin interactions in the intravenous glucose tolerance test. Applied Mathematical Sciences, 8(66), , [17] P. Herrero, B. Delaunay, L. Jaulin, P. Georgiou, N. Oliver and C. Toumazou. Robust set-membership parameter estimation of the glucose minimal model. International Journal Adaptive Control Signal Processing, DOI: /acs.2538, [18] R. Bergman. Minimal model: perspective from Hormone Research, 64(3), 8-15, [19] M. Fisher. A semiclosed-loop algorithm for the control of blood glucose levels in diabetics. IEEE Transactions on Biomedical Engineering, 38(1), 57-61, [20] A. Caumo, R. Bergman and C. Cobelli. Insulin Sensitivity from Meal Tolerance Tests in Normal Subjects: A Minimal Model Index. The Journal of Clinical Endocrinology & Metabolism, 85(11), , [21] N. Hernajak and J. Doyle III. Glucose Control Design Using Nonlinearity Assessment Techniques. American Institute of Chemical Engineers Journal, 51(2), , [22] P. Dua, F. Doyle III and E. Pistikopoulos. Model-Based Blood Glucose Control for Type 1 Diabetes via Parametric Programming. IEEE Transactions on Biomedical Engineering, 53(8), , [23] K. Lunze, T. Singh and S. Leonhardt. Modeling of Glucose-Insulin System Dynamics in Diabetic Goettingen Minipigs. Biological and Medical Systems, 8(1), , [24] M. Berger and D. Rodbard. Computer simulation of plasma insulin and glucose dynamics after subcutaneous insulin injection. DiabetesCare, 12(10), , [25] E. Friis-Jensen Modeling and Simulation of Glucose-Insulin Metabolism. PhD Thesis, Technical University of Denmark, Kongens Lyngby, Denmark, May, APPENDIX TABLE I PATIENT CONSTANT PARAMETERS USED IN THE MODEL. Parameter Value G b, basal value of glucose (mg/dl) 200 I b, basal value of insulin (mu/l) 15 V G, glucose distribution volume per kg 0.22 body weight (L/kg) V I, insulin distribution volume per kg body weight (L/kg) m BW, body weight (kg) p 1, glucose clearance rate independent of insulin (min 1 ) p 2, decreasing level of insulin action with time (min 1 ) p 3, increase in uptake ability caused by 5.035e 5 insulin ((μu/ml) 1 min 2 ) n, decay rate of blood insulin (mu/l) 0.22 γ, rate of pancreatic release after glucose mu dl bolus ( L mg min ) h, pancreatic target glycemia level (mg/dl) 83.7 a i, regular insulin parameter (h/u 1 ) 0.05 b i, regular insulin parameter (h) 1.7 s i, regular insulin parameter 2 R utl, rate of utilization
CLOSED LOOP MODEL FOR GLUCOSE INSULIN REGULATION SYSTEM USING LABVIEW
CLOSED LOOP MODEL FOR GLUCOSE INSULIN REGULATION SYSTEM USING LABVIEW 1 P Srinivas 2 P.Durga Prasada Rao 1 Associate Professor, Department of EIE, VR Siddhartha Engineering College, Vijayawada, India Email:
More informationAN INTELLIGENT SUPPORT SYSTEM FOR DIABETIC PATIENTS
AN INTELLIGENT SUPPORT SYSTEM FOR DIABETIC PATIENTS Mark Hoogendoorn, Michel C. A. Klein, Nataliya M. Mogles VU University Amsterdam, Department of Artificial Intelligence, De Boelelaan 1081, Amsterdam,
More informationA Fuzzy Controller for Blood Glucose-Insulin System
Journal of Signal and Information Processing, 213, 4, 111-117 http://dx.doi.org/1.4236/jsip.213.4215 Published Online May 213 (http://www.scirp.org/journal/jsip) 111 Ahmed Y. Ben Sasi 1, Mahmud A. Elmalki
More informationCONTROL SYSTEM FOR INSULIN PUMPS IN THE MELLITUS DIABETES TREATMENTS
CONTROL SYSTEM FOR INSULIN PUMPS IN THE MELLITUS DIABETES TREATMENTS 1. INTRODUCTION The mellitus diabetes is a chronic disease that develops a great risk of progression of diabetes complications: diabetes
More informationInsulin dosage based on risk index of Postprandial Hypo- and Hyperglycemia in Type 1 Diabetes Mellitus with uncertain parameters and food intake
based on risk index of Postprandial Hypo- and Hyperglycemia in Type 1 Diabetes Mellitus with uncertain parameters and food intake Remei Calm 1, Maira García-Jaramillo 1, Jorge Bondia 2, Josep Vehí 1 1
More informationSelf-tuning Insulin Adjustment Algorithm for Type I Diabetic Patients Based on Multi-Doses Regime.
International Simposium on Robotics and Automation 24 August 25-27, 24 Self-tuning Adjustment Algorithm for Type I Diabetic Patients Based on Multi-Doses Regime. D.U. Campos-Delgado Facultad de Ciencias
More informationAn Improved PID Switching Control Strategy for Type 1 Diabetes
An Improved PID Switching Control Strategy for Type 1 Diabetes Gianni Marchetti, Massimiliano Barolo, Lois Jovanovic, Howard Zisser, and Dale E. Seborg, Member, IEEE Department of Chemical Engineering
More informationThe Exploitation of Using Sliding Table Controller in Blood Glucose-Insulin System for Diabetes
The Exploitation of Using Sliding Table Controller in Blood Glucose-Insulin System for Diabetes Ahmed Y. Ben Sasi College of Industrial Technology Misurata, Libya ahmed_bensasi@yahoo.co.uk Mahmud A. Elmalki
More informationDeterministic and Stochastic Modeling of Insulin Sensitivity
Deterministic and Stochastic Modeling of Insulin Sensitivity Master s Thesis in Engineering Mathematics and Computational Science ELÍN ÖSP VILHJÁLMSDÓTTIR Department of Mathematical Science Chalmers University
More informationHomeostatic Model Assessment (HOMA)
Homeostatic Model Assessment (HOMA) Historically, insulin resistance (IR) was measured with an invasive test called a euglycemic clamp test. Basically it s a test to measure how much insulin a person needs
More informationA Virtual Type 1 Diabetes Patient
Hochschule für Angewandte Wissenschaften Hamburg University of Applied Sciences Hamburg Fakultät für Medizintechnik Department for Biomedical Engineering Bachelor Thesis A Virtual Type 1 Diabetes Patient
More informationDiabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus
Melissa Meredith M.D. Diabetes mellitus is a group of metabolic diseases characterized by high blood glucose resulting from defects in insulin secretion, insulin action, or both Diabetes is a chronic,
More informationAbdulaziz Al-Subaie. Anfal Al-Shalwi
Abdulaziz Al-Subaie Anfal Al-Shalwi Introduction what is diabetes mellitus? A chronic metabolic disorder characterized by high blood glucose level caused by insulin deficiency and sometimes accompanied
More informationDiabetes mellitus. Lecture Outline
Diabetes mellitus Lecture Outline I. Diagnosis II. Epidemiology III. Causes of diabetes IV. Health Problems and Diabetes V. Treating Diabetes VI. Physical activity and diabetes 1 Diabetes Disorder characterized
More informationOverview of Diabetes Management. By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health
Overview of Diabetes Management By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health Objectives: Describe the pathophysiology of diabetes. From a multiorgan systems viewpoint. Identify the types of diabetes.
More informationTitle: Using Formal Methods to Improve Safety of Home-Use Medical Devices
Title: Using Formal Methods to Improve Safety of Home-Use Medical Devices Authors: Ayan Banerjee Impact Lab, Arizona State University abanerj3@asu.edu Yi Zhang Center for Devices and Radiological Health,
More informationMinimal Models for Glucose and Insulin Kinetics
Minimal Models for Glucose and Insulin Kinetics Daniel R. Kerner, PhD. Civilized Software, Inc. 12109 Heritage Park Circle Silver Spring MD 20906 Tel.: (301)-962-3711 email: csi@civilized.com URL: www.civilized.com
More informationtips Insulin Pump Users 1 Early detection of insulin deprivation in continuous subcutaneous 2 Population Study of Pediatric Ketoacidosis in Sweden:
tips Top International Publications Selection Insulin Pump Users Early detection of insulin deprivation in continuous subcutaneous insulin infusion-treated Patients with TD Population Study of Pediatric
More informationARTICLE IN PRESS Biomedical Signal Processing and Control xxx (2012) xxx xxx
Biomedical Signal Processing and Control xxx (2012) xxx xxx Contents lists available at SciVerse ScienceDirect Biomedical Signal Processing and Control journa l h omepage: www.elsevier.com/locate/bspc
More informationAutomatic Blood Glucose Control in Diabetes
Automatic Blood Glucose Control in Diabetes Marit Owren Master of Science in Engineering Cybernetics Submission date: June 29 Supervisor: Bjarne Anton Foss, ITK Norwegian University of Science and Technology
More informationBasal Rate Testing Blood sugar is affected at any time by 1) basal insulin 2) food (carbohydrate) intake 3) bolus insulin (meal time and correction)
Basal Rate Testing Blood sugar is affected at any time by 1) basal insulin 2) food (carbohydrate) intake 3) bolus insulin (meal time and correction) 4) activity and 5) other factors such as stress and
More informationIntroduction. We hope this guide will aide you and your staff in creating a safe and supportive environment for your students challenged by diabetes.
Introduction Diabetes is a chronic disease that affects the body s ability to metabolize food. The body converts much of the food we eat into glucose, the body s main source of energy. Glucose is carried
More informationDepartment Of Biochemistry. Subject: Diabetes Mellitus. Supervisor: Dr.Hazim Allawi & Dr.Omar Akram Prepared by : Shahad Ismael. 2 nd stage.
Department Of Biochemistry Subject: Diabetes Mellitus Supervisor: Dr.Hazim Allawi & Dr.Omar Akram Prepared by : Shahad Ismael. 2 nd stage. Diabetes mellitus : Type 1 & Type 2 What is diabestes mellitus?
More informationINSULIN PRODUCTS. Jack DeRuiter
INSULIN PRODUCTS Jack DeRuiter The number and types of insulin preparations available in the United States is constantly changing, thus students should refer to recent drug resources for a current list
More informationThe Background for the Diabetes Detection Model
The Background for the Diabetes Detection Model James K. Peterson Department of Biological Sciences and Department of Mathematical Sciences Clemson University November 23, 2014 Outline The Background for
More informationDELAY DIFFERENTIAL EQUATIONS IN MODELING INSULIN THERAPIES FOR DIABETES
DELAY DIFFERENTIAL EQUATIONS IN MODELING INSULIN THERAPIES FOR DIABETES Final year project submitted to the Dept. of Mathematics of the University of Portsmouth May 2008 By Emma Geraghty B.Sc. (Hons) Mathematics
More informationCauses, incidence, and risk factors
Causes, incidence, and risk factors Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused by too little insulin, resistance to insulin, or both. To understand diabetes,
More informationCLASS OBJECTIVES. Describe the history of insulin discovery List types of insulin Define indications and dosages Review case studies
Insulins CLASS OBJECTIVES Describe the history of insulin discovery List types of insulin Define indications and dosages Review case studies INVENTION OF INSULIN 1921 The first stills used to make insulin
More informationAdvisors: Masahiko Saito, Mathematics and Statistics Scott Campbell, Chemical & Biomedical Engineering. Problem Suggested By: Scott Campbell
Undergraduate Journal of Mathematical Modeling: One + Two Volume 3 2011 Spring Issue 2 Article 12 Blood Glucose Levels Carlos Estela University of South Florida Advisors: Masahiko Saito, Mathematics and
More informationClass time required: Two 40-minute class periods + homework. Part 1 may be done as pre-lab homework
Diagnosing Diabetes Teacher information Summary: Students analyze simulated blood plasma samples collected during a glucose tolerance test for diabetes. They test glucose and insulin levels to determine
More informationCalculating Insulin Dose
Calculating Insulin Dose First, some basic things to know about insulin: Approximately 40-50% of the total daily insulin dose is to replace insulin overnight, when you are fasting and between meals. This
More informationAdocia reports positive results from phase IIa clinical study of ultra-fast acting BioChaperone Lispro
PRESS RELEASE Adocia reports positive results from phase IIa clinical study of ultra-fast acting BioChaperone Lispro BioChaperone Lispro is significantly faster than Humalog in type I diabetic patients;
More informationMonitoring and Carbohydrate Counting: The Cornerstones of Diabetes Control. Linda Macdonald, M.D. November 19, 2008
Monitoring and Carbohydrate Counting: The Cornerstones of Diabetes Control Linda Macdonald, M.D. November 19, 2008 Objectives Understand the relationship between insulin, carbohydrate intake, and blood
More informationETIOLOGIC CLASSIFICATION. Type I diabetes Type II diabetes
DIABETES MELLITUS DEFINITION It is a common, chronic, metabolic syndrome characterized by hyperglycemia as a cardinal biochemical feature. Resulting from absolute lack of insulin. Abnormal metabolism of
More informationA Type 1 Diabetic Model. A Thesis. Submitted to the Faculty. Drexel University. Brian Ray Hipszer. in partial fulfillment of the
A Type 1 Diabetic Model A Thesis Submitted to the Faculty of Drexel University by Brian Ray Hipszer in partial fulfillment of the requirements for the degree of Master of Science September 2001 iii Dedication
More informationAlgorithms for Glycemic Management of Type 2 Diabetes
KENTUCKY DIABETES NETWORK, INC. Algorithms for Glycemic Management of Type 2 Diabetes The Diabetes Care Algorithms for Type 2 Diabetes included within this document are taken from the American Association
More informationX-Plain Hypoglycemia Reference Summary
X-Plain Hypoglycemia Reference Summary Introduction Hypoglycemia is a condition that causes blood sugar level to drop dangerously low. It mostly shows up in diabetic patients who take insulin. When recognized
More informationDRUGS FOR GLUCOSE MANAGEMENT AND DIABETES
Page 1 DRUGS FOR GLUCOSE MANAGEMENT AND DIABETES Drugs to know are: Actrapid HM Humulin R, L, U Penmix SUNALI MEHTA The three principal hormones produced by the pancreas are: Insulin: nutrient metabolism:
More informationObjectives PERINATAL INSULIN PUMPS: BASICS FOR NURSES. Historical Perspective. Insulin Pumps in Pregnancy. Insulin Pumps in the US
Objectives PERINATAL INSULIN PUMPS: BASICS FOR NURSES Jo M. Kendrick, APN BC, CDE jkendric@utmck.edu Describe indications and contraindications for insulin pump use in hospitalized patients Differentiate
More informationBasal Insulin Analogues Where are We Now?
232 Medicine Update 41 Basal Insulin Analogues Where are We Now? S CHANDRU, V MOHAN Insulin is a polypeptide secreted by the beta cells of pancreas and consists of 51 amino acids (AA). It has two polypeptide
More informationInsulin therapy in various type 1 diabetes patients workshop
Insulin therapy in various type 1 diabetes patients workshop Bruce H.R. Wolffenbuttel, MD PhD Dept of Endocrinology, UMC Groningen website: www.umcg.net & www.gmed.nl Twitter: @bhrw Case no. 1 Male of
More informationHow you can achieve normal blood sugars with diet and insulin. Dr Katharine Morrison IDDT October 2007
How you can achieve normal blood sugars with diet and insulin Dr Katharine Morrison IDDT October 2007 Me and my boys Dr. Richard Bernstein People do not get complications and die from having diabetes.
More informationExternal Insulin Pumps Corporate Medical Policy
External Insulin Pumps Corporate Medical Policy File name: External Insulin Pumps File code: UM.DME.02 Origination: 4/2006 Last Review: 02/2014 (ICD-10 remediation only) Next Review: 10/2014 Effective
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Haidar A, Legault L, Matteau-Pelletier L, et
More informationPowerPoint Lecture Outlines prepared by Dr. Lana Zinger, QCC CUNY. 12a. FOCUS ON Your Risk for Diabetes. Copyright 2011 Pearson Education, Inc.
PowerPoint Lecture Outlines prepared by Dr. Lana Zinger, QCC CUNY 12a FOCUS ON Your Risk for Diabetes Your Risk for Diabetes! Since 1980,Diabetes has increased by 50 %. Diabetes has increased by 70 percent
More informationDiabetes mellitus 1 عبد هللا الزعبي. pharmacology. Shatha Khalil Shahwan. 1 P a g e
Diabetes mellitus 1 pharmacology عبد هللا الزعبي 1 P a g e 4 Shatha Khalil Shahwan Diabetes mellitus The goals of the treatment of diabetes 1. Treating symptoms 2. Treating and Preventing acute complications
More informationDiabetes. New Trends Presented by Barbara Obst RN MS August 2008
Diabetes New Trends Presented by Barbara Obst RN MS August 2008 What is Diabetes Diabetes is a condition characterized by high levels of glucose. The glucose circulates in your blood and serves as the
More informationUniversita degli Studi di Padova Facolta di Ingegneria
Universita degli Studi di Padova Facolta di Ingegneria Finito di scrivere il giorno September 5, 01 utilizzando L A TEX ε UNIVERSITÀ DEGLI STUDI DI PADOVA FACOLTÀ DI INGEGNERIA Dipartimento di Ingegneria
More informationInsulin kinetics during HyperInsulinemia Euglycemia Therapy (HIET)
Insulin kinetics during HyperInsulinemia Euglycemia Therapy (HIET) S. Penning 1, P. Massion 2, A.J. Le Compte 3, T. Desaive 1 and J.G. Chase 3 1 Cardiovascular Research Centre, University of Liege, Liege,
More informationDiabetes Medications: Insulin Therapy
Diabetes Medications: Insulin Therapy Courtesy Univ Texas San Antonio Eric L. Johnson, M.D. Department of Family and Community Medicine Diabetes and Insulin Type 1 Diabetes Autoimmune destruction of beta
More informationRobust Control of Type 1 Diabetes using µ-synthesis
Robust Control of Type 1 Diabetes using µ-synthesis Levente Kovács, András György, Balázs Kulcsár, Péter Szalay, Balázs Benyó, Zoltán Benyó Department of Control Engineering and Information Technology,
More informationWhat is Type 2 Diabetes?
Type 2 Diabetes What is Type 2 Diabetes? Diabetes is a condition where there is too much glucose in the blood. Our pancreas produces a hormone called insulin. Insulin works to regulate our blood glucose
More informationType 1 Diabetes - Managing a Critical Ratio
Objectives Students will learn about how ratios and proportions are a key part of managing Type 1 Diabetes Students will learn about the regulation of blood glucose through insulin (hormone) binding with
More informationInsulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused by too little insulin, resistance to insulin, or both.
Diabetes Definition Diabetes is a chronic (lifelong) disease marked by high levels of sugar in the blood. Causes Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused
More informationTuberculosis And Diabetes. Dr. hanan abuelrus Prof.of internal medicine Assiut University
Tuberculosis And Diabetes Dr. hanan abuelrus Prof.of internal medicine Assiut University TUBERCULOSIS FACTS More than 9 million people fall sick with tuberculosis (TB) every year. Over 1.5 million die
More informationDR. Trinh Thi Kim Hue
TYPE 2 DIABETES IN THE CHILD AND ADOLESCENT DR. Trinh Thi Kim Hue CONTENTS Definition Diagnosis Treatment Comorbidities and Complications Comorbidities and Complications Screening for T2D References DEFINITION
More informationContinuous Subcutaneous Insulin Infusion (CSII)
IMPORTANCE OF FOCUS CSII (Insulin pumps) have been used for more than 35 years. In the U.S. in 2005, the level of insulin pump penetration was estimated at 20 to 30% in patients with type 1 diabetes mellitus
More informationINSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT?
INSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT? MARTHA M. BRINSKO, MSN, ANP-BC CHARLOTTE COMMUNITY HEALTH CLINIC CHARLOTTE, NC Diagnosed and undiagnosed diabetes in the United
More informationDIABETES MELLITUS. By Tracey Steenkamp Biokineticist at the Institute for Sport Research, University of Pretoria
DIABETES MELLITUS By Tracey Steenkamp Biokineticist at the Institute for Sport Research, University of Pretoria What is Diabetes Diabetes Mellitus (commonly referred to as diabetes ) is a chronic medical
More informationINSULIN INTENSIFICATION: Taking Care to the Next Level
INSULIN INTENSIFICATION: Taking Care to the Next Level By J. Robin Conway M.D., Diabetes Clinic, Smiths Falls, ON www.diabetesclinic.ca Type 2 Diabetes is an increasing problem in our society, due largely
More informationTypes of insulin and How to Use Them
Diabetes and Insulin Pumps Amy S. Pullen Pharm.D ISHP Spring Meeting April 2012 Objectives Describe the different types of insulin used in diabetes Identify the types of insulin that are compatible with
More informationInsulin Pump Therapy and Continuous Glucose Sensor Use in the Management of Diabetes Mellitus
Insulin Pump Therapy and Continuous Glucose Sensor Use in the Management of Diabetes Mellitus Louis Haenel, IV, DO, FACOI, FACE Endocrinology Roper Hospital Charleston, SC Dr. Louis Haenel IV has disclosed
More informationCME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus
CME Test for AMDA Clinical Practice Guideline Diabetes Mellitus Part I: 1. Which one of the following statements about type 2 diabetes is not accurate? a. Diabetics are at increased risk of experiencing
More informationIV solutions may be given either as a bolus dose or infused slowly through a vein into the plasma at a constant or zero-order rate.
د.شيماء Biopharmaceutics INTRAVENOUS INFUSION: IV solutions may be given either as a bolus dose or infused slowly through a vein into the plasma at a constant or zero-order rate. The main advantage for
More informationShould We Count Fat and Protein in Bolus Insulin Dose Calculation: Does Carbohydrate Counting Work? Howard A. Wolpert, MD
Should We Count Fat and Protein in Bolus Insulin Dose Calculation: Does Carbohydrate Counting Work? Howard A. Wolpert, MD Carbohydrate to Insulin Ratio, circa 1935 Standard Insulin Replacement Regimen
More informationglucose and fatty acids to raise your blood sugar levels.
Endocrine & Cell Communication Part IV: Maintaining Balance (Homeostasis) TEACHER NOTES needs coding 1 Endocrine & Cell Communication Part IV: Maintaining Balance (Homeostasis) 2 AP Biology Curriculum
More information嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯
The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized
More informationINJEX Self Study Program Part 1
INJEX Self Study Program Part 1 What is Diabetes? Diabetes is a disease in which the body does not produce or properly use insulin. Diabetes is a disorder of metabolism -- the way our bodies use digested
More informationIntensive Insulin Therapy in Diabetes Management
Intensive Insulin Therapy in Diabetes Management Lillian F. Lien, MD Medical Director, Duke Inpatient Diabetes Management Assistant Professor of Medicine Division of Endocrinology, Metabolism, & Nutrition
More informationDiabetes Health Care Plan
The Public Schools of Brookline School Health Services of Plan: Diabetes Health Care Plan To be completed by the student s health care team and parents/guardian. Plan will be kept with the school nurse
More informationNONINSULIN-DEPENDENT diabetes mellitus
0021-972X/97/$03.00/0 Vol. 82, No. 8 Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright 1997 by The Endocrine Society An Overnight Insulin Infusion Algorithm Provides Morning
More informationThe first injection of insulin was given on
EFFECTIVE USE OF INSULIN THERAPY IN TYPE 2 DIABETES * Bernard Zinman, MDCM ABSTRACT Type 2 diabetes is a progressive disease; an individual s ability to secrete insulin in increasing amounts to overcome
More informationInsulin onset, peak and duration of action
Insulin onset, peak and duration of action Insulin was first discovered in the early 190 s. Before then, diabetes could not be treated. Insulin was then taken from cow and pig pancreases, but nearly all
More informationTaking Insulin Pumps to School. Rachel Calendo, MS, RN, CPNP, CDE, Martha Cuevas, RN, BSN, CPT
Taking Insulin Pumps to School Rachel Calendo, MS, RN, CPNP, CDE, Martha Cuevas, RN, BSN, CPT Insulin Pumps Today A micro-computer, about the size of a pager Programmed to deliver both a preset amount
More informationINPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco
INPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco CLINICAL RECOGNITION Background: Appropriate inpatient glycemic
More informationThere seem to be inconsistencies regarding diabetic management in
Society of Ambulatory Anesthesia (SAMBA) Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Review of the consensus statement and additional
More information4/7/2015 CONFLICT OF INTEREST DISCLOSURE OBJECTIVES. Conflicts of Interest None Heather Rush. Heather M. Rush, APRN, CDE Louisville, KY
Heather M. Rush, APRN, CDE Louisville, KY CONFLICT OF INTEREST DISCLOSURE Conflicts of Interest None Heather Rush A conflict of interest exists when an individual is in a position to profit directly or
More informationModel Predictive Control Algorithms for Pen and Pump Insulin Administration
Ph.D. Thesis Model Predictive Control Algorithms for Pen and Pump Insulin Administration Dimitri Boiroux Department of Informatics and Mathematical Modelling Technical University of Denmark Kongens Lyngby
More informationReference. United States. 1. Introduction
572 F. Doyle et al. / Journal of Process Control 17 (2007) 571 594 and actuators with sufficient authority to influence the controlled variables. As always, plant understanding is key. Biological systems
More informationDiabetes and Technology. Disclosures Certified Insulin Pump Trainer for: Animas Medtronic Diabetes Omnipod. Rebecca Ray, MSN, APRN, FNP-C
Diabetes and Technology Rebecca Ray, MSN, APRN, FNP-C Insulin Pump Therapy and Continuous Glucose Monitoring In Patients with Type 2 Diabetes Page 1 Disclosures Certified Insulin Pump Trainer for: Animas
More informationImplications of Meal Library & Meal Detection to Glycemic Control of Type 1 Diabetes Mellitus through MPC Control
Proceedings of the 17th World Congress The International Federation of Automatic Control Seoul, Korea, July 6-11, 28 Implications of Meal Library & Meal Detection to Glycemic Control of Type 1 Diabetes
More informationInsulin Therapy. Endocrinologist. H. Delshad M.D. Research Institute For Endocrine Sciences
Insulin Therapy H. Delshad M.D Endocrinologist Research Institute For Endocrine Sciences Primary Objectives of Effective Management A1C % 9 8 Diagnosis SBP mm Hg LDL mg/dl 7 145 130 140 100 Reduction of
More informationPractical Applications of Insulin Pump Therapy in Type 2 Diabetes
Practical Applications of Insulin Pump Therapy in Type 2 Diabetes Wendy Lane, MD For a CME/CEU version of this article please go to www.namcp.org/cmeonline.htm, and then click the activity title. Summary
More informationThe Quantified Self on Steroids: Innovation in Devices, Pumps and Monitors
The Quantified Self on Steroids: Innovation in Devices, Pumps and Monitors Howard A. Wolpert, MD 1 Diabetes is different to many other conditions Patient/Self Managed 2 To achieve the therapeutic goals
More informationThe effect of physical exercise on the dynamics of glucose and insulin
Journal of Biomechanics 35 (22) 911 917 The effect of physical exercise on the dynamics of and insulin M. Derouich, A. Boutayeb* D!epartement de math!ematiques et informatique, Facult!e des Sciences, Universit!e
More informationTHE EFFECT OF SODIUM CHLORIDE ON THE GLUCOSE TOLERANCE OF THE DIABETIC RAT*
THE EFFECT OF SODIUM CHLORIDE ON THE GLUCOSE TOLERANCE OF THE DIABETIC RAT* BY JAMES M. ORTEN AND HENRY B. DEVLINt (From the Deparkment of Physiological Chemistry, Wayne University College of Medicine,
More informationThe Diabetes Self Management Insulin Pump Therapy Program
The Diabetes Self Management Insulin Pump Therapy Program Is part of a Nationally recognized program taught by CPT s Offers classes during the daytime in a three part series: PRE-PUMP CLASS SALINE START
More informationManagement of Diabetes in the Elderly. Sylvia Shamanna Internal Medicine (R1)
Management of Diabetes in the Elderly Sylvia Shamanna Internal Medicine (R1) Case 74 year old female with frontal temporal lobe dementia admitted for prolonged delirium and frequent falls (usually in the
More informationALVIN INDEPENDENT SCHOOL DISTRICT Diabetes Medical Management Plan
ALVIN INDEPENDENT SCHOOL DISTRICT Diabetes Medical Management Plan of Plan: School Year (must be current): This plan should be completed by the student s personal health care team and parents/guardian.
More informationDisclosures. Types of Diabetes Mellitus. Type 1 Diabetes Mellitus. Principles of Basal-Bolus Insulin Therapy and Carbohydrate Counting
Principles of Basal-Bolus Insulin Therapy and Carbohydrate Counting Disclosures I do not have any relevant financial relationships with any commercial interests. Henry K. Driscoll, MD, FACP Huntington
More informationOFFICE OF CATHOLIC SCHOOLS DIOCESE OF ARLINGTON DIABETES MEDICAL MANAGEMENT PLAN Page 1 of 5 TO BE COMPLETED BY PARENT OR GUARDIAN
PART I OFFICE OF CATHOLIC SCHOOLS DIOCESE OF ARLINGTON DIABETES MEDICAL MANAGEMENT PLAN Page 1 of 5 TO BE COMPLETED BY PARENT OR GUARDIAN Student School Date of Birth Date of Diagnosis Grade/ Teacher Physical
More informationDIABETIC EDUCATION MODULE ONE GENERAL OVERVIEW OF TREATMENT AND SAFETY
DIABETIC EDUCATION MODULE ONE GENERAL OVERVIEW OF TREATMENT AND SAFETY First Edition September 17, 1997 Kevin King R.N., B.S., C.C.R.N. Gregg Kunder R.N., B.S.N., C.C.T.C. 77-120 CHS UCLA Medical Center
More informationLab 2. Spectrophotometric Measurement of Glucose
Lab 2 Spectrophotometric Measurement of Glucose Objectives 1. Learn how to use a spectrophotometer. 2. Produce a glucose standard curve. 3. Perform a glucose assay. Safety Precautions Glucose Color Reagent
More information2. What Should Advocates Know About Diabetes? O
2. What Should Advocates Know About Diabetes? O ften a school district s failure to properly address the needs of a student with diabetes is due not to bad faith, but to ignorance or a lack of accurate
More informationNCT00272090. sanofi-aventis HOE901_3507. insulin glargine
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationDiabetes Management and Treatment Plan for School (For the insulin pump student)
Lafayette School Corporation Health Services Diabetes Management and Treatment Plan for School (For the insulin pump student) Effective Dates: This plan should be complete by the student s personal health
More informationX-Plain Diabetes - Introduction Reference Summary
X-Plain Diabetes - Introduction Reference Summary Introduction Diabetes is a disease that affects millions of Americans every year. Your doctor may have informed you that you have diabetes. Although there
More informationSafe use of insulin e- learning module
Safe use of insulin e- learning module Page 1 Introduction Insulin is a hormone produced by the beta cells in the pancreas, it is released when blood glucose levels are raised for example after a meal.
More informationDynamic Process Modeling. Process Dynamics and Control
Dynamic Process Modeling Process Dynamics and Control 1 Description of process dynamics Classes of models What do we need for control? Modeling for control Mechanical Systems Modeling Electrical circuits
More informationLead Clinician(S) (DATE) Approved by Diabetes Directorate on: Approved by Medicines Safety Group on: This guideline should not be used after end of:
Guideline for members of the diabetes team and dietetic department for advising on insulin dose adjustment and teaching the skills of insulin dose adjustment to adults with type 1 or type 2 diabetes mellitus
More information